Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate HCl Clear all
Completed Phase 3 Interventional Results available

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

NCT00541346
View directory record Official record
Conditions
Autism, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

NCT00264797
View directory record Official record
Conditions
ADHD, Substance Abuse
Interventions
Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Not applicable Interventional Results available

Role of Apathy in the Effectiveness of Weight Loss Interventions

NCT00548652
View directory record Official record
Conditions
Obesity, Apathy
Interventions
MOVE, medical crisis councelling, methyphenidate
Behavioral · Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for Attention Problems After Pediatric TBI

NCT01933217
View directory record Official record
Conditions
Traumatic Brain Injury, TBI, ADHD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 17, 2026, 1:35 PM EDT
Enrolling by invitation Phase 1 Interventional

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

NCT05301361
View directory record Official record
Conditions
Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Oral Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 24 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00501293
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 1:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

NCT04421248
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Combined
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Other
Eligibility
8 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children

NCT00754208
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
4 Years to 5 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

NCT00178503
View directory record Official record
Conditions
Autism, Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

Psychopharmacology for Cocaine Dependence - Buspirone

NCT01267292
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo for Buspirone, Methylphenidate, Placebo for Methylphenidate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

NCT02822937
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate, Triazolam, Project: EVO, Placebo
Drug · Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

NCT05685732
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Drug · Other
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional

Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial

NCT05041946
View directory record Official record
Conditions
Fatigue, Cancer
Interventions
Methylphenidate, Placebo (Sugar Pill)
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 2 Interventional

Methylphenidate and Parkinson's Disease

NCT00359723
View directory record Official record
Conditions
Parkinson's Disease
Interventions
methylphenidate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 17, 2026, 1:35 PM EDT
Completed Early Phase 1 Interventional

Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954
View directory record Official record
Conditions
Normal Physiology, Opioid Use Disorders
Interventions
[11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 1:35 PM EDT